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Abstract
Guanosine-specific cyclic nucleotide signaling is suggested to serve protective actions in the
vasculature; however, the influence of selective pharmacologic modulation of cyclic guanosine
monophosphate (GMP)-synthesizing soluble guanylate cyclase (sGC) or cyclic GMP-degrading
phosphodiesterase (PDE) on vessel remodeling has not been thoroughly examined. In this study, rat
carotid artery balloon injury was performed and the growth-modulating effects of the sGC stimulator
YC-1 or the cGMP-dependent PDE-V inhibitor zaprinast were examined. YC-1 or zaprinast elevated
vessel cyclic GMP content, reduced medial wall and neointimal cell proliferation, stimulated medial
and neointimal cellular apoptosis, and markedly attenuated neointimal remodeling in comparable
fashion. Interestingly, sGC inhibition by ODQ failed to noticeably alter neointimal growth, and
concomitant zaprinast with YC-1 did not modify any parameter compared to individual treatments.
These results provide novel in vivo evidence that YC-1 and zaprinast inhibit injury-induced vascular
remodeling through anti-mitogenic and pro-apoptotic actions and may offer promising therapeutic
approaches against vasoproliferative disorders.
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Introduction
The soluble guanylate cyclase (sGC)/cyclic guanosine monophosphate (GMP) signal
transduction system plays an important regulatory role in the cardiovascular system. The
vasoactive influence of sGC/cyclic GMP-stimulatory nitric oxide (NO) has been extensively
studied and well characterized. More recently, our laboratory has helped identify the heme
oxygenase (HO)/carbon monoxide (CO) system as a robust cyclic GMP-stimulating pathway
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following vascular injury.1-3 Synthesized cyclic GMP exerts physiologic and
pathophysiologic effects through multiple signaling pathways including direct activation of
cyclic GMP-dependent protein kinase (PK-G), direct and/or indirect cross-talk with the cyclic
adenosine monophosphate (AMP)/cyclic AMP-dependent protein kinase (PK-A) system, or
hydrolytic degradation by cyclic GMP-dependent phosphodiesterase (PDE-V).
Based principally on its protective effects in cardiac and vascular tissues, much emphasis has
been placed on identifying upstream pharmacologic activators or stimulators of the sGC/cyclic
GMP system. YC-1 (3-(5′-hydroxymethyl-2′-furyl)-1-benzylindazole), originally
characterized as a potent sGC activator in platelets,4,5 has been shown to protect against
vascular smooth muscle injury through multiple growth-inhibitory properties.6-10 In similar
fashion BAY 41-2272, a potent YC-1-based sGC stimulator, has been recently suggested to
serve beneficial actions against aberrant vascular smooth muscle growth.11 An alternate route
for inducing salutary cyclic GMP signaling is through selective inhibition of cyclic GMP-
degrading PDE, an approach successfully used to combat a variety of vascular disorders with
perhaps the most popular being those used to treat sexual dysfunction. Zaprinast [1,4-
dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimidine-7-one], a selective
inhibitor of cyclic GMP-specific PDE-V, significantly elevates cyclic GMP and downstream
signaling in the vasculature.12,13 Several studies cite protective actions of zaprinast in hypoxic
pulmonary vasculature,14 during capillary leakage and edema,15 or on platelet function
following arterial injury,16 while several others have shown beneficial effects of cyclic AMP-
specific PDE-3 inhibition on vessel growth;17-19 however, the influence of the PDE-V
inhibitor zaprinast on the growth response to vascular injury is scientifically provocative yet
has not been described in the literature.
Using YC-1 for comparison, the present study addressed the hypothesis that the selective cyclic
GMP-dependent PDE-V inhibitor zaprinast attenuates remodeling in rat balloon-injured
carotid arteries. Novel results demonstrate that both YC-1 and zaprinast elevate vessel cyclic
GMP content, reduce vascular cell proliferation and stimulate apoptosis, and attenuate
neointimal growth in similar manner. Furthermore, lack of significant ODQ and combined
YC-1 and zaprinast effects suggest that YC-1 and zaprinast share common signaling pathways
in the injury growth response and that these occur irrespective of upstream cyclase
involvement.
Materials and Methods
Rat carotid artery balloon injury model
Experimental balloon injury was performed on the rat left carotid artery (LCA) as described.
20 Briefly, male Sprague Dawley rats (520 ± 10 g; Harlan, Indianapolis, IN) were anesthetized
(ketamine, xylazine, and acepromazine; 0.5 - 0.7 ml/kg IM; VetMed Drugs) and a Fogarty 2F
embolectomy catheter (Baxter Healthcare Corp.) was introduced through an external carotid
arteriotomy site and advanced through the LCA, inflated, and withdrawn thrice. The exposed
portion of the injured LCA was treated accordingly (see Dosing Protocol below), tissues were
closed in layers, and animals were given buprenorphine (0.5 mg/kg, SC) for analgesia. At
specific times, anesthetized rats were euthanized by pneumothorax and exsanguination and
tissues were harvested for specific protocols. All procedures conformed to the Guide for the
Care and Use of Laboratory Animals, published by the U.S. National Institutes of Health (NIH
Publication No. 85-23, revised 1996), and were approved by the Institutional Animal Care and
Use Committee (IACUC).
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Topical administration of pharmacologic agents immediately followed balloon injury.6,21
Two hundred μl of a 25% copolymer gel solution (Pluronic F-127; BASF) containing 1 mg
zaprinast (Calbiochem-Novabiochem Corp.), YC-1 (Calbiochem, LaJolla, CA), or the specific
sGC inhibitor 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ; Calbiochem-
Novabiochem Corp.), or a combination thereof, in 50 μl DMSO was administered to the
exposed LCA adventitia. Control animals received 200 μl gel containing 50 μl DMSO. Animals
were closed and allowed to recover until euthanasia.
Tissue processing and staining
Perfusion-fixed, paraffin embedded tissues were used for standard staining techniques, and
microscopic analysis and quantitation of morphologic parameters were performed.21 Fresh
tissues were snap-frozen and used for the cyclic GMP assay.6
Cyclic GMP radioimmunoassay
The protocol used for measuring cyclic GMP in vascular tissue followed that supplied with
the 125I-labeled cyclic GMP competitive radioimmunoassay (RIA) kit (Amersham
Biosciences).6 Forty-eight hours after injury animals were sacrificed and fresh tissues were
obtained and snap-frozen. Similarly-treated tissues were pooled (n = 3-5 animals/group) and
the RIA was performed. Tissues were homogenized in cold 6% trichloroacetic acid,
centrifuged, and the cyclic GMP-containing supernatant removed and ether-washed. Cyclic
GMP-containing extract was dried and resuspended in 200 μl assay buffer. Samples were
acetylated and working standards were prepared. Sections of rat thoracic aorta were used as
positive controls for cyclic GMP.22
Proliferating cell nuclear antigen (PCNA) and TUNEL assays
Immunostaining for PCNA for estimating cell proliferation was performed on balloon-injured
rat LCAs.1 Tissues were treated with an anti-PCNA monoclonal antibody (PC-10; 1:25;
Sigma) complemented with a biotinylated anti-mouse secondary antibody (1:100), followed
by an avidin-biotin block and DAB chromogen with nuclear fast red counterstain. Data are
represented as a PCNA labeling index (LI), defined as the percentage of total cells positive for
PCNA staining within a given area.1 Rat balloon-injured LCAs were stained for apoptotic
nuclei using an In Situ Cell Death Detection kit (Roche Molecular Biochemicals) as described.
1 Tissues were treated with proteinase K, endogenous peroxidase activity was blocked, and
tissues were exposed to avidin-biotin block with antigen retrieval. Tissues were incubated with
TUNEL reaction mixture and treated with converter-peroxidase solution. Tissues were serially
treated with DAB and hematoxylin. Data are represented as a TUNEL LI. Conventional light
microscopy was performed on TUNEL-positive cells to confirm morphologic characteristics
of apoptosis.
Statistical analysis
Data were stored and analyzed on personal computers using Excel 2003 (Microsoft), Sigma
Plot 8.0 with Sigma Stat for Windows (v. 3.0; SPSS, Inc.), Instat (v. 3.06; GraphPad Software
Inc.), and Origin 7 SR1 (v. 7.0; OriginLab Corporation). Data were grouped according to
treatment and analyzed using a one-way ANOVA with post-hoc Holm-Sidak test for pairwise
comparisons. All data are represented as mean ±standard error of the mean (SEM). A p-value
< 0.05 is considered statistically significant for all comparisons.
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Rat carotid artery balloon injury model
Representative photomicrographs of rat balloon-injured LCAs 14 days post-injury are shown
in Figure 1. An injured LCA treated with empty hydrogel (Fig. 1A) exhibits a concentric and
significant neointima with a clearly defined medial wall and elastic laminae. Figure 1B shows
an injured zaprinast-treated LCA with a significantly attenuated neointima, appearing
sporadically as a thin non-concentric layer adjacent to the internal lamina. Figure 1C illustrates
an injured YC-1-treated LCA and similarly shows reduced neointimal development. Figure
1D shows an injured LCA treated with combined zaprinast and YC-1, and a significantly
diminished neointima is observed yet no additive effect is seen compared to individual
zaprinast- or YC-1-treated sections. Figure 1E shows an ODQ-treated vessel with a significant
and concentric neointima (similar to controls), while Figure 1F shows an ODQ and YC-1-
treated vessel. Corresponding histomorphometric data obtained 14 days post-injury are shown
in Figure 2. Figures 2A, 2C, and 2D clearly show significant and comparable attenuation of
neointimal growth in injured LCAs treated with zaprinast, YC-1, or zaprinast plus YC-1
compared to vehicle controls. Separate cohorts of injured arteries treated with ODQ failed to
show observable changes in neointima formation relative to vehicle controls, and arteries
exposed to combined ODQ and YC-1 failed to fully reverse the YC-1-inhibitory effects on
neointimal growth. Interestingly, LCAs exposed to zaprinast, either alone or in combination
with YC-1, displayed significant medial wall enlargement compared to vehicle controls (Fig.
2B). Analyses of the circumferences of LCA internal and external elastic laminae between all
treatment groups revealed no significant differences after 14 days (data not shown).
Cyclic GMP
Zaprinast stimulated a significant 2.7-fold increase in cyclic GMP content in injured LCAs
compared to injured vehicle controls (61.61 ±5.62 vs. 23.04 ±2.30 fmol/mg protein,
respectively) 48 hours post-injury. At this time YC-1 also markedly elevated vessel cyclic
GMP levels compared to controls (35.45 ±2.2 vs. 22.12 ±4.3 fmol/mg protein, respectively),
substantiating previously observed findings.6 Interestingly, combined zaprinast and YC-1
failed to increase cyclic GMP over that observed in the zaprinast-only treated group (63.66
±3.12 vs. 61.61 ±5.62 fmol/mg protein, respectively). Rat balloon-injured LCAs exposed to
empty hydrogel (vehicle controls) did not demonstrate altered cyclic GMP compared to
untreated injured sections, and uninjured LCAs treated with zaprinast and/or YC-1 did not
show changes in cyclic GMP levels compared to uninjured untreated sections (data not shown).
PCNA and TUNEL
Temporal analyses of vessel wall DNA replication, performed by PCNA immunostaining, were
performed 1, 2, 7 and 14 days following injury (Fig. 3). Data show markedly reduced PCNA
staining in zaprinast- and YC-1-treated groups in both the medial wall (Fig. 3A) and neointima
(Fig. 3B) at all time points. In complement, medial cell counts were significantly reduced in
the zaprinast group compared to controls at 2 (304.5 ±7.5 vs. 339.3 ±7.3; p < 0.05) and 14
(371.3 ±24.7 vs. 603.5 ±71.9; p < 0.05) days post-injury, while neointimal cell counts were
significantly reduced in the zaprinast group compared to controls after 14 days (226.8 ±26.2
vs. 1072.5 ±100.5; p < 0.001). Similarly, YC-1 potently reduced cellularity in the media after
1 (256.0 ±12.6 vs. 375.3 ±9.3; p < 0.01), 2 (260.7 ±4.7 vs. 339.3 ±7.3; p < 0.001), and 14 (401.3
±32.8 vs. 603.5 ±71.9; NS, p = 0.06) days and in the neointima after14 days (172.8 ±37.5 vs.
1072.5 ±100.5; p < 0.001) compared to controls.
Figure 4 illustrates results from TUNEL immunostaining for LCA medial and neointimal cell
apoptosis 14 days post-injury. Marked pro-apoptotic effects from zaprinast or YC-1 are clearly
evident. Vessel wall TUNEL results at 1, 2, and 7 days post-injury revealed no specific trend
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for apoptosis (data not shown). TUNEL-positive cells consistently exhibited marked cellular
contraction, nuclear condensation, and intracellular cytoplasmic blebbing observed via light
microscopy by an independent observer (data not shown).
Discussion
The current study shows for the first time that the selective cyclic GMP-dependent PDE-V
inhibitor zaprinast confers protection against vascular growth following experimental injury.
In the rat carotid artery balloon injury model, peri-operative zaprinast significantly elevated
vessel cyclic GMP levels and markedly inhibited neointimal growth through anti-proliferative
and pro-apoptotic avenues. Analogous effects were observed with the sGC stimulator YC-1,
and combined YC-1 with zaprinast failed to show discernable effects over individual
treatments, thus suggesting that these agents operate via similar signaling pathways. Moreover,
cyclase inhibition by ODQ failed to exert demonstrable impact on vessel growth, implying that
these phenomena occur in sGC-independent fashion. Indeed, these provocative results offer in
vivo insights into the mechanisms of action of these upstream and downstream cyclic GMP
modulators and suggest promising therapeutic approaches for the treatment of vascular
proliferative disorders.
In this study zaprinast significantly elevated cyclic GMP in injured arteries in the same range
as that reported in rat primary vascular smooth muscle following growth factor
stimulation23 and in rat cardiac tissue after natriuretic peptide stimulation.24 We observed that
YC-1 also increased vessel cyclic GMP after injury, substantiating earlier results in this same
model6 and in a separate study using rat primary vascular smooth muscle cells.7 These results
support bioactivity of cyclic GMP signaling by zaprinast and YC-1 in this experimental in vivo
model. Interestingly, in this study concomitant zaprinast with YC-1 failed to induce cyclic
GMP over that observed with zaprinast alone, suggesting common pathways exist for these
agents in this experimental setting. This is highly plausible considering that YC-1 exerts potent
(IC50 = 10 μM) PDE-V inhibition in addition to its well documented cyclase-stimulatory
actions.25,26 These remarkable results suggest that YC-1 may operate primarily through
downstream PDE-V inhibition in vascular tissues following trauma. A recent article showing
that YC-1 attenuates homotypic neutrophil aggregation primarily through inhibition of PDE
activity27 supports this theory. Conversely, these findings may also infer that sGC is fully
activated in the zaprinast treated injured vessel and is therefore unable to synthesize additional
cyclic GMP in the presence of a stimulatory agonist such as YC-1.
Vascular growth is largely dependent upon a balance between tissue gain and loss, critical
parameters for therapeutic targeting. Zaprinast or YC-1 significantly and equally attenuated
injury-induced neointimal growth in the rat carotid artery (Figs. 1 and 2), suggesting that these
agents operate via similar mechanisms in their growth-reducing effects. Conversely, these
findings may also suggest that growth inhibition from these compounds is maximal and has
reached a plateau and that further reduction in growth via additive, synergistic or potentiative
avenues is not possible under these experimental conditions. Further study is warranted with
these promising agents, perhaps at lower doses than those used in the current investigation, to
address this possibility. Interestingly, zaprinast, alone or in conjunction with YC-1, resulted
in medial wall enlargement in addition to its attenuating effects on neointimal formation. This
is an apparent paradox, considering that zaprinast significantly inhibited medial cell DNA and
cellular replication and stimulated medial cell apoptosis, processes that eventuate in loss of
medial wall architecture and integrity. Current investigations into potential mechanisms that
could contribute to an enlarged medial area from zaprinast, which may include directional cell
migration, altered production of extracellular matrix (ECM) components, or changes in ECM-
degrading metalloproteinases (MMPs), should prove insightful and may offer potential
underlying mechanisms.
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The inhibitory effects of zaprinast on vascular DNA replication and cellularity observed in this
study support recent reports of the cytostatic actions of zaprinast on cells of different origins.
28-30 We now provide first evidence that zaprinast can directly reduce proliferation of vascular
cells following experimental injury. Zaprinast has been found to potentiate NO-mediated
apoptosis in megakaryocytes31 and natriuretic peptide-induced apoptosis in rat cardiac
myocytes32 and pulmonary endothelium,30 although zaprinast itself has been suggested to
lack apoptotic capacity.33 Considering earlier results showing that balloon injury upregulated
sGC-sensitizing NO synthase and HO enzymes,6 herein we provide novel data showing potent
pro-apoptotic effects of zaprinast in vascular tissues after injury. The pro-apoptotic effects of
YC-1 observed in this report corroborate previous findings that YC-1 stimulates apoptosis in
neutrophils34 and in adrenomedullary endothelial and chromaffin cells,35 possibly through
caspase-3-like protease activity in fashion independent of sGC.35
A recent article provides strong evidence that cyclic GMP/PK-G signaling is not involved in
the protective effects of NO during vascular remodeling.36 Experiments using ODQ in the
current report suggest that sGC is not involved in zaprinast- or YC-1-mediated vascular growth
inhibition, yet cumulative findings also suggest that zaprinast and YC-1 share common
signaling pathways, that is, through inhibition of cyclic GMP-degrading PDE-V with ensuing
cyclic GMP-dependent actions. Differences in experimental models (arterial ligation or wire
denudation versus balloon distension) and species (mouse versus rat) as well as distinct
upstream activating ligands (NO versus CO) must be considered when comparing such studies.
Conclusions
Herein we demonstrate that the cyclic GMP-dependent PDE-V inhibitor zaprinast provides
protection against vessel growth after injury through inhibition of vascular cell proliferation
and induction of apoptosis. Analogous results with the sGC stimulator YC-1 suggest that YC-1
and zaprinast operate through parallel pathways in the vascular growth response following
trauma. Also, lack of noticeable effects from concomitant YC-1 and zaprinast suggest that
these agents operate in sGC-independent fashion under these experimental conditions. This
new evidence provides insights into the mechanisms and potential therapeutic applicability of
the cyclic GMP modulators YC-1 and zaprinast for the treatment of vasculoproliferative
disorders.
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Figure 1. Photomicrographs of rat balloon-injured carotid arteries
Representative photomicrographs of rat balloon-injured, perfusion-fixed Verhoeff-van
Gieson-stained left carotid arteries (LCAs) 14 days post-injury. Immediately following injury
LCAs were treated with vehicle (A) or vehicle containing zaprinast (B), YC-1 (C), zaprinast
+ YC-1 (D), ODQ (E), or ODQ + YC-1 (F). Scale bar in (A) represents a length of 100 μm.
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Figure 2. Histomorphometric data for rat balloon-injured carotid arteries
Morphologic parameters 14 days following balloon injury for rat left carotid arteries (LCAs)
treated with vehicle, zaprinast, YC-1, zaprinast + YC-1, ODQ, or ODQ + YC-1 immediately
after injury. Neointimal growth (A, C, D) is significantly attenuated in the zaprinast, YC-1,
and zaprinast + YC-1 groups. Significant medial wall enlargement is detected in both zaprinast-
treated groups (B). ODQ failed to significantly alter neointimal growth or medial wall
morphology relative to controls. Animal numbers: n = 7 for vehicle, n = 9 for YC-1, n = 8 for
zaprinast, zaprinast + YC-1, ODQ, and ODQ + YC-1 groups. Values represent mean ±SEM.
* p < .05, ** p < .01, *** p < .001 versus vehicle.
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Figure 3. Vessel wall PCNA immunostaining
Medial wall (A) and neointimal (B) PCNA labeling indices (LI%) for rat left carotid arteries
(LCAs) 1, 2, 7, or 14 days following balloon injury. Immediately following injury LCAs were
treated with vehicle or with vehicle containing zaprinast or YC-1. Zaprinast or YC-1 robustly
and equally reduced medial and neointimal cell proliferation at all time points compared to
controls. Animal numbers: n = 3-5/group/time point. Values represent mean ±SEM. * p < 0.05,
** p < 0.01, *** p < 0.001 versus vehicle.
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Figure 4. Vessel wall TUNEL staining
Medial and neointimal TUNEL immunostaining on rat balloon-injured left carotid arteries
(LCAs) after 14 days reveals robust apoptosis in the zaprinast- or YC-1-treated LCAs compared
to controls. Animal numbers: n = 3-5/group/time point. Values represent mean ±SEM. * p <
0.05, ** p < 0.01, *** p < 0.001 versus vehicle.
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